BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24875069)

  • 1. Serotonin-norepinephrine reuptake inhibitor-associated mixed episode in an adolescent with schizoaffective disorder.
    Chang JP; Chi MH; Chiu YN; Tsai WC; Gau SS; Shang CY
    J Clin Psychopharmacol; 2014 Aug; 34(4):525-6. PubMed ID: 24875069
    [No Abstract]   [Full Text] [Related]  

  • 2. Manic switching in patients receiving duloxetine.
    de Dios C; Ezquiaga E
    Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
    [No Abstract]   [Full Text] [Related]  

  • 3. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
    Lee SI; Keltner NL
    Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
    Ashton AK; Longdon MC
    Am J Psychiatry; 2007 Jul; 164(7):1121-2. PubMed ID: 17606668
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine-induced cutaneous adverse reaction.
    Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
    J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of apical ballooning cardiomyopathy associated with duloxetine.
    Bergman BR; Reynolds HR; Skolnick AH; Castillo D
    Ann Intern Med; 2008 Aug; 149(3):218-9. PubMed ID: 18678857
    [No Abstract]   [Full Text] [Related]  

  • 8. Burning paresthesia related to duloxetine therapy.
    Woo YS; Bahk WM
    J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of hyponatremia induced by duloxetine.
    Safdieh JE; Rudominer R
    J Clin Psychopharmacol; 2006 Dec; 26(6):675-6. PubMed ID: 17110834
    [No Abstract]   [Full Text] [Related]  

  • 10. [Duloxetine reduces pain and depression].
    Krankenpfl J; 2004; 42(7-10):246-7. PubMed ID: 15675408
    [No Abstract]   [Full Text] [Related]  

  • 11. Duloxetine-induced nocturnal bruxism resolved by buspirone: case report.
    Albayrak Y; Ekinci O
    Clin Neuropharmacol; 2011; 34(4):137-8. PubMed ID: 21768799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digging for data on harms in duloxetine trials.
    Doshi P; Zito J; dosReis S
    BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
    Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
    Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
    Ravindran LN; Eisfeld BS; Kennedy SH
    J Clin Psychopharmacol; 2008 Feb; 28(1):107-8. PubMed ID: 18204355
    [No Abstract]   [Full Text] [Related]  

  • 15. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
    Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding gums: duloxetine may be the cause.
    Balhara Y; Sagar R; Varghese ST
    J Postgrad Med; 2007; 53(1):44-5. PubMed ID: 17244971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive monitoring of duloxetine: results of a web-based intensive monitoring study.
    Härmark L; van Puijenbroek E; van Grootheest K
    Eur J Clin Pharmacol; 2013 Feb; 69(2):209-15. PubMed ID: 22688722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.
    Dell'osso B; Mundo E; Marazziti D; Altamura AC
    J Psychopharmacol; 2008 Mar; 22(2):210-3. PubMed ID: 18208931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.
    Trivedi MH; Desaiah D; Ossanna MJ; Pritchett YL; Brannan SK; Detke MJ
    Int Clin Psychopharmacol; 2008 May; 23(3):161-9. PubMed ID: 18408530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine: a dual reuptake inhibitor.
    Dugan SE; Fuller MA
    Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.